Sarcoid-like reaction related to ALK-ROS inhibitors in lung cancer patients

被引：0
|
作者：
Morin, Clara [1 ,2 ]
Villeneuve, Thomas [1 ]
Norkowski, Emma [3 ]
Rosencher, Lise [4 ,5 ]
Cadranel, Jacques [4 ,5 ]
Mazieres, Julien [1 ,2 ]
机构：
[1] Univ Hosp Toulouse, Pulmonol Dept, 24 Chemin Pouvourville, F-31059 Toulouse, France
[2] Univ Toulouse III Paul Sabatier, Ctr Rech Cancerol Toulouse CRCT, Inserm, CNRS, 2 Ave Hubert Curien, F-31100 Toulouse, France
[3] Medipath, Pathol, 116 Route Espagne, F-31100 Toulouse, France
[4] Hop Tenon, AP HP, Pulmonol & Thorac Oncol Dept, 4 Rue Chine, F-75020 Paris, France
[5] Sorbonne Univ, 4 Rue Chine, F-75020 Paris, France
来源：
RESPIRATORY MEDICINE AND RESEARCH | 2024年 / 86卷
关键词：
Non-small cell lung cancer; ALK; ROS1; Targeted therapy; Drug-induced sarcoidosis-like reaction; Safety;
D O I：
10.1016/j.resmer.2024.101138
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer
    Rapoport, Bernardo
    Arani, Ramin B.
    Mathieson, Nicola
    Krendyukov, Andriy
    FUTURE ONCOLOGY, 2019, 15 (18) : 2163 - 2174
  • [32] Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing
    Jurmeister, Philipp
    Lenze, Dido
    Berg, Erika
    Mende, Stefanie
    Schaeper, Frank
    Kellner, Udo
    Herbst, Hermann
    Sers, Christine
    Budczies, Jan
    Dietel, Manfred
    Hummel, Michael
    von Laffert, Maximilian
    LUNG CANCER, 2015, 87 (02) : 122 - 129
  • [33] ALK Gene Rearrangement in Patients with Lung Cancer in Northern Mexican Population
    Lopez Resendiz, K. E.
    Barboza Quintana, O.
    Garza Guajardo, R.
    Vilches Cisneros, N.
    Flores Gutierrez, J. P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1174 - S1174
  • [34] The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
    Dagogo-Jack, Ibiayi
    Ritterhouse, Lauren L.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2557 - 2570
  • [35] Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
    Gibson, Amanda J. W.
    Box, Adrian
    Dean, Michelle L.
    Elegbede, Anifat A.
    Hao, Desiree
    Sangha, Randeep
    Bebb, Gwyn
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (04):
  • [36] Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?
    Han, B.
    Zhang, B.
    Xu, J.
    Zhang, Y.
    Zhang, X.
    Chu, T.
    Wang, S.
    Qiao, R.
    Qian, J.
    Lu, J.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S471 - S471
  • [37] Long-term treatment with ALK inhibitors for postoperative recurrence of ALK-rearranged lung cancer
    Ken Kodama
    Yukio Kimura
    Toru Momozane
    Kaichi Sigetsu
    Masashi Takeda
    Hiroki Kishima
    International Cancer Conference Journal, 2022, 11 : 238 - 241
  • [38] Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+Non-Small-Cell Lung Cancer (NSCLC)
    Felip, E.
    Bauer, T.
    Solomon, Benjamin
    Besse, B.
    James, L.
    Clancy, J.
    Klamerus, K.
    Martini, J. -F.
    Abbattista, A.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S383 - S384
  • [39] Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients
    Song, Zhengbo
    Yu, Xinmin
    Zhang, Yiping
    CANCER BIOLOGY & THERAPY, 2017, 18 (11) : 883 - 887
  • [40] Long-term treatment with ALK inhibitors for postoperative recurrence of ALK-rearranged lung cancer
    Kodama, Ken
    Kimura, Yukio
    Momozane, Toru
    Sigetsu, Kaichi
    Takeda, Masashi
    Kishima, Hiroki
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2022, 11 (04) : 238 - 241
12345